I was wondering about the possibility of the DSMB triggering an early mCRC trial stoppage for overwhelming Leronlimab efficacy. IF we're lucky enough for it to eventually happen (and it admittedly might be a longshot, however I do think it's possible given the impressive publicly revealed open-label trial data so far), here's how it works and how it could benefit CYDY shareholders and patients:
The DSMB regularly reviews unblinded data to ensure patient safety and can recommend stopping a study if the treatment's benefits are so clear and statistically significant that continuing the trial would be ethically unjustified. While stopping a trial early for overwhelming efficacy is a recognized protocol in clinical research, it is rarely done. Because this is an open-label, Phase 2 study with a smaller sample size, the threshold for a DSMB to halt it for overwhelming efficacy is high. If the DSMB were to identify an overwhelming, undeniable survival benefit, it could recommend terminating the trial early to allow for expedited regulatory actions, such as submitting a Biologics License Application (BLA).
If a Data and Safety Monitoring Board (DSMB) stops a trial early for overwhelming efficacy, it significantly accelerates the Biologics License Application (BLA) timeline. A DSMB halt changes the BLA trajectory through specific regulatory mechanisms:
-Triggering an Accelerated Approval Pathway
If a trial is stopped early based on a highly predictive surrogate endpoint (like the rapid drop in ctDNA seen in CytoDyn's recent AACR data updates), the FDA can grant Accelerated Approval. This allows the company to submit a BLA and market the drug based on the Phase 2 data alone , rather than waiting years to complete a Phase 3 trial.
-Priority Review Designation
A trial stopped for overwhelming efficacy automatically qualifies a drug for Priority Review.
If the drug has an active Fast Track or Breakthrough Therapy Designation, a DSMB stop allows for a Rolling Review.
The company does not have to wait until every single administrative section of the BLA is finished. They can submit completed modules (e.g., preclinical data, manufacturing data) to the FDA for review piece-by-piece, dramatically shortening the final approval timeline. CytoDyn also retains completed sections from their prior HIV BLA that may be eligible for submission, further expediting the process.
_________________________________________________________________
One would imagine mCRC and Leronlimab could (hopefully) become an FDA priority given the following sad news: https://www.scientificamerican.com/article/co...er-cancer/
_________________________________________________________________
I remain... #BULLISH
https://www.youtube.com/watch?v=nvlTJrNJ5lA&
#DRJAY #LERONLIMAB #CYDY #CCR5 #SAVINGLIVES #DRKASI #DRPESTELL #OPENLABEL #ctDNA #CRC #COLDTOHOT #ALZ #mTNBC #IMPECCABLE_SAFETY #MAKINGWAVES #OUTERLIMITS #OPENWATERS
The DSMB regularly reviews unblinded data to ensure patient safety and can recommend stopping a study if the treatment's benefits are so clear and statistically significant that continuing the trial would be ethically unjustified. While stopping a trial early for overwhelming efficacy is a recognized protocol in clinical research, it is rarely done. Because this is an open-label, Phase 2 study with a smaller sample size, the threshold for a DSMB to halt it for overwhelming efficacy is high. If the DSMB were to identify an overwhelming, undeniable survival benefit, it could recommend terminating the trial early to allow for expedited regulatory actions, such as submitting a Biologics License Application (BLA).
If a Data and Safety Monitoring Board (DSMB) stops a trial early for overwhelming efficacy, it significantly accelerates the Biologics License Application (BLA) timeline. A DSMB halt changes the BLA trajectory through specific regulatory mechanisms:
-Triggering an Accelerated Approval Pathway
If a trial is stopped early based on a highly predictive surrogate endpoint (like the rapid drop in ctDNA seen in CytoDyn's recent AACR data updates), the FDA can grant Accelerated Approval. This allows the company to submit a BLA and market the drug based on the Phase 2 data alone , rather than waiting years to complete a Phase 3 trial.
-Priority Review Designation
A trial stopped for overwhelming efficacy automatically qualifies a drug for Priority Review.
If the drug has an active Fast Track or Breakthrough Therapy Designation, a DSMB stop allows for a Rolling Review.
The company does not have to wait until every single administrative section of the BLA is finished. They can submit completed modules (e.g., preclinical data, manufacturing data) to the FDA for review piece-by-piece, dramatically shortening the final approval timeline. CytoDyn also retains completed sections from their prior HIV BLA that may be eligible for submission, further expediting the process.
_________________________________________________________________
One would imagine mCRC and Leronlimab could (hopefully) become an FDA priority given the following sad news: https://www.scientificamerican.com/article/co...er-cancer/
_________________________________________________________________
I remain... #BULLISH
https://www.youtube.com/watch?v=nvlTJrNJ5lA&
#DRJAY #LERONLIMAB #CYDY #CCR5 #SAVINGLIVES #DRKASI #DRPESTELL #OPENLABEL #ctDNA #CRC #COLDTOHOT #ALZ #mTNBC #IMPECCABLE_SAFETY #MAKINGWAVES #OUTERLIMITS #OPENWATERS
14
